M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Iron and monoamine oxidase activity are increased in brain of Parkinson's disease (PD). They are associated with autoxidation and oxidative deamination of dopamine by MAO resulting in the generation of reactive oxygen species and the onset of oxidative stress to induce neurodegeneration. Iron chelators (desferal, Vk-28 and clioquinol) but not copper chelators have been shown to be neuroprotective in the 6-hydroxydoapmine and MPTP models of Parkinson's disease (PD), as are monoamine oxidase B inhibitors such as selegiline and rasagiline. These findings prompted the development of multifunctional anti PD drugs possessing iron chelating phamacophore of VK-28 and the propargylamine MAO inhibitory activity of rasagiline. M30 is a potent iron chelator, radical scavenger and brain selective irreversible MAO-A and B inhibitor, with little inhibition of peripheral MAO. It has neuroprotective activity in in vitro and in vivo models of PD and unlike selective MAO-B inhibitors it increases brain dopamine, serotonin and noradrenaline. These findings indicate beside its anti PD action, it may also possess antidepressant activity, similar to selective MAO-A and nonselective MAO inhibitors. These properties make it an ideal anti PD drug for which it is being developed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Iron chelators inhibit these inimical processes (Gal et al. 2006; Perez et al. 2008; Xu et al. 2008; Youdim et al. 2004a, b; Zheng et al. 2005), including (Kaur et al. 2003; Reznichenko et al. 2010; Youdim 2003) in the case of a Parkinson-like disease induced (Blum et al. 2001; Choi et al. 2009; Gal et al. 2009; Yokoyama et al. 2008) by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) (ChEBI”
Citations
Cites
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationHalliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502 · cited 2×
“It is well established that chelatable (ionic) iron can induce oxidative stress because of its interaction with hydrogen peroxide and to generate reactive hydroxyl radical, which is known to initiate a process of membrane lipid peroxidation that results in cell membrane fluidity and finally cell death by a further cas…”
BackgroundBasal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Self-citationIron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971
Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?
Gerlach, M., Ben‐Shachar, D., Riederer, P., & Youdim, M. B. H. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63030793.x · Cited by 703
Self-citationGenetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Lin, Y., & Lin, J. (1997) · PubMed · Cited by 539
Lin, Y.-L., & Lin, J.-K. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.3.465 · Cited by 463
Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases
Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445
Self-citationMulti-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Self-citationGr�nblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., Li, J., Ravid, R., Roggendorf, W., Riederer, P., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0212-1 · Cited by 356
Self-citationMultifunctional Activities of Green Tea Catechins in Neuroprotection
Mandel, S. A., Avramovich-Tirosh, Y., Reznichenko, L., Zheng, H., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Neurosignals · doi:10.1159/000085385 · Cited by 347
Self-citationIron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313
Self-citationThe possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301
Self-citationBen‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299
Self-citationInhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
Glinka, Y. Y., & Youdim, M. B. H. (1995) · European Journal of Pharmacology: Environmental Toxicology and Pharmacology · doi:10.1016/0926-6917(95)90040-3 · Cited by 283
Self-citationZheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B. H., & Fridkin, M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.10.037 · Cited by 278
Self-citationSterling, J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., Miskolczi, I., Molnar, S., Rantal, F., Tamas, T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020120c · Cited by 247
Self-citationShachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246
Self-citationYOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233
Self-citationO'Carroll, A.-M., Fowler, C. J., Phillips, J. P., Tobbia, I., & Tipton, K. F. (1983) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00500765 · Cited by 230
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218 · cited 2×
“Parkinson’s Disease (PD) brain studies point to an on going oxidative stress and inflammatory processes, that may be involved in the increase in iron deposition and increased MAO activity in the substantia nigra pars compacta (SNpc) in the pathology of nigrostriatal dopamine neuron degeneration (Berg et al., 1999; Dex…”
BackgroundZheng, H., Gal, S., Weiner, L. M., Bar‐Am, O., Warshawsky, A., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03340.x · Cited by 214
Self-citationMelatonin is protective against MPTP-induced striatal and hippocampal lesions
Acuña-Castroviejo, D., Coto-Montes, A., Monti, M. G., Ortiz, G. G., & Reiter, R. J. (1996) · Life Sciences · doi:10.1016/s0024-3205(96)00606-6 · Cited by 199
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185
Self-citationThe etiology of Parkinson's disease with emphasis on the MPTP story
Langston, J. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.153s · Cited by 180
Perry, T. L., Yong, V. W., Clavier, R. M., Jones, K., Wright, J. M., Foulks, J. G., & Wall, R. A. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90229-0 · Cited by 177
Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine
Glinka, Y., Tipton, K. F., & Youdim, M. B. H. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66052004.x · Cited by 176
Self-citationUse of desferrioxamine in the treatment of aceruloplasminemia
Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., & Gitlin, J. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410318 · Cited by 173
Iron accumulation in the substantia nigra in rats visualized by ultrasound
Berg, D., Grote, C., Rausch, W.-D., Mäurer, M., Wesemann, W., Riederer, P., & Becker, G. (1999) · Ultrasound in Medicine & Biology · doi:10.1016/s0301-5629(99)00046-0 · Cited by 165
Cadet, J. L., Katz, M., Jackson-Lewis, V., & Fahn, S. (1989) · Brain Research · doi:10.1016/0006-8993(89)91530-8 · Cited by 163
Youdim, M. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00103-7 · Cited by 160
Self-citationDesferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
Lan, J., & Jiang, D. H. (1997) · Journal of Neural Transmission · doi:10.1007/bf01277665 · Cited by 159
Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156 · cited 2×
“It is well established that intranigral or intraventricular 6-OHDA initiates an increase of total iron in the substantia nigra and striatum, at the sites of neurodegeneration, both in monkeys, rats and mice (Hall et al., 1992; Lin et al., 1997; Lin and Lin, 1997; Oestreicher et al., 1994).”
BackgroundIn Vitro Studies of Ferritin Iron Release and Neurotoxicity
Double, K. L., Maywald, M., Schmittel, M., Riederer, P., & Gerlach, M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70062492.x · Cited by 152
GREEN, A. R., MITCHELL, B. D., TORDOFF, A. F. C., & YOUDIM, M. B. H. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07506.x · Cited by 145
Self-citationFrost, E. A. M. (1989) · Journal of Neurosurgical Anesthesiology · doi:10.1097/00008506-198903000-00016 · Cited by 140
Temlett, J. A., Landsberg, J. P., Watt, F., & Orime, G. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010134.x · Cited by 137
Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages
Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., & Tsukamoto, H. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.272.6.g1355 · Cited by 133
Mochizuki, H., Imai, H., Endo, K., Yokomizo, K., Murata, Y., Hattori, N., & Mizuno, Y. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90462-6 · Cited by 132
Lamensdorf, I., Youdim, M. B. H., & Finberg, J. P. M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67041532.x · Cited by 131
Self-citationWeinstock, M., Bejar, C., Wang, R.-H., Poltyrev, T., Gross, A., Finberg, J. P. M., & Youdim, M. B. H. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_10 · Cited by 125
Self-citation6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation
Monteiro, H. P., & Winterbourn, C. C. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90512-1 · Cited by 125 · cited 1×
“It may depend on their abilities to release iron from ferritin, as well as to down regulate transferrin receptors and up regulate divalent metal transporter at the cell surface membrane, which can be prevented by iron chelators such as desferal (Monteiro and Winterbourn, 1989; Double et al., 1998; Linert et al., 1996;…”
BackgroundYoudim, M. B. H., Fridkin, M., & Zheng, H. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0143-x · Cited by 123
Self-citationRoghani, M., & Behzadi, G. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03296-0 · Cited by 118
Moussaoui, S. M., Obinu, M. C., Daniel, N., Reibaud, M., Blanchard, V., & Impérato, A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7516 · Cited by 116
Oxidative Stress, Mitochondrial Respiration, and Parkinson's Disease
COHEN, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06180.x · Cited by 115
Lan, J., & Jiang, D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291883 · Cited by 105
Iron alters glutamate secretion by regulating cytosolic aconitase activity
McGahan, M. C., Harned, J., Mukunnemkeril, M., Goralska, M., Fleisher, L., & Ferrell, J. B. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00444.2004 · Cited by 85
Gassen, M., & Youdim, M. B. H. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00390.x · Cited by 79
Self-citationDopamine-Dependent Iron Toxicity in Cells Derived from Rat Hypothalamus
Paris, I., Martinez-Alvarado, P., Cárdenas, S., Perez-Pastene, C., Graumann, R., Fuentes, P., Olea-Azar, C., Caviedes, P., & Segura-Aguilar, J. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0497144 · Cited by 74 · cited 1×
“On several occasions dopamine metabolism via autoxidation and by the reaction of MAO has been implicated to induce degeneration of nigrostriatal dopamine neurons (Riederer et al., 1989; Paris et al., 2005) (Fig.”
BackgroundFinberg, J. P. M., & Youdim, M. B. H. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00216-2 · Cited by 72
Self-citationMelatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system
Kim, Y. S., Joo, W. S., Jin, B. K., Cho, Y. H., Baik, H. H., & Park, C. W. (1998) · Neuroreport · doi:10.1097/00001756-199807130-00043 · Cited by 68
Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo
Ferger, B., Spratt, C., Teismann, P., SEITZ, G., & Kuschinsky, K. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00696-7 · Cited by 55
MRI, brain iron and experimental Parkinson's disease
Hall, S., Rutledge, J. N., & Schallert, T. J. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90247-i · Cited by 49
Rasagiline: an anti-Parkinson drug with neuroprotective activity
Youdim, M. B. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.6.737 · Cited by 48
Self-citationWeinstock, M., Gorodetsky, E. K., Wang, R. H., Gross, A., Weinreb, O., & Youdim, M. B. H. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00176-4 · Cited by 37
Self-citationGoto, K., Mochizuki, H., Imai, H., Akiyama, H., & Mizuno, Y. (1996) · Brain Research · doi:10.1016/0006-8993(96)00284-3 · Cited by 32
Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea‐pig
Ilani, T., Lamensdorf, I., & Finberg, J. P. M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703493 · Cited by 14
Research works printed but not linked: 1
- Foley F, Gerlach M, Youdim MBH, Riederer P (2000) MAO-B inhibitors: multiple roles in the therapy of neurodegenerative diseases. PARD 6: 25–47
Cited by
Metals in Alzheimer's and Parkinson's Diseases
Barnham, K. J., & Bush, A. I. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.019 · Cited by 695
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications
Prachayasittikul, V., Prachayasittikul, V., Prachayasittikul, S., & Ruchirawat, S. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s49763 · Cited by 445
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential
Song, Y., Xu, H., Chen, W., Zhan, P., & Liu, X. (2015) · MedChemComm · doi:10.1039/c4md00284a · Cited by 235
Metadata
- Authors
- Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Weizmann Institute of Science (IL)
- Venue
- Parkinson’s Disease and Related Disorders
- Publisher
- Springer Vienna
- Published
- 2006
- Issue
- 70
- Pages
- 447-456
- OpenAlex
- W2179417997
- Cited by
- 58
- References
- 65
- Citations by year
- 2024: 4 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 5 · 2012: 5
- FWCI
- 6.61
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Springer eBooks (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- M30, Parkinson's disease, iron chelation, monoamine oxidase inhibition, monoamine oxidase A, monoamine oxidase B, neuroprotection, oxidative stress, dopamine autoxidation, reactive oxygen species, antidepressant effects, propargylamines, 6-hydroxydopamine model, MPTP model, dopamine, serotonin, norepinephrine
- MeSH terms
- Animals, Brain, Dopamine, Humans, Hydroxyquinolines, Iron Chelating Agents, Monoamine Oxidase Inhibitors, Synaptic Transmission, Parkinson Disease, Dopamine Agents, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.